Telix Unveils 1st Cyclotron Facility in Asia-Pacific in Japan

The facility is expected to support clinical supply of TLX250-CDx, Telix's kidney cancer imaging candidate, and with plans to expand to other diagnostic and therapeutic products for prostate and brain cancer, subject to regulatory approvals.

Telix Pharmaceuticals has inaugurated Telix Manufacturing Solutions (TMS) in Yokohama, Japan, marking its first cyclotron facility in the Asia-Pacific region.

The facility is expected to support clinical supply of TLX250-CDx, Telix's kidney cancer imaging candidate, and with plans to expand to other diagnostic and therapeutic products for prostate and brain cancer, subject to regulatory approvals.

Commenting on the new launch, Raphael Ortiz, CEO International Business and Japan President at Telix, stated, "The opening of TMS Yokohama is a significant milestone for Telix as it enhances our capacity to meet growing demand for radiopharmaceuticals in Japan and the Asia Pacific. As the world's second-largest nuclear medicine market, we have always considered Japan a key country in our clinical and commercial strategy. Today demonstrates our commitment to the Japanese community, to scientific excellence, and to the well-being of patients throughout the region."

Founded in 2015, Telix Pharma and headquartered in Melbourne, Australia, develops theranostic radiopharmaceuticals and associated medical technologies for cancer care.

The company is advancing a pipeline of clinical and commercial-stage products aimed at addressing unmet medical needs in oncology and rare diseases.

TMS, Telix’s manufacturing network, currently includes about 39 production and distribution facilities across five continents. Its capabilities cover isotope production, translational research, radiochemistry, antibody engineering, bioconjugation, and the manufacturing and distribution of finished radiopharmaceutical products.

Stay tuned for more such updates on Digital Health News